HCPCS Code Descriptor:
Injection, eribulin mesylate, 0.1 mg
Route of Administration:
HALAVEN is an Oncology drug manufactured by Eisai and administered via the Intravenous route of administration. The J Code: J9179 is aligned to the drug HALAVEN.